Companies › ZetrOZ
1 active drug program in 4 registered trials: 2 Phase 1, 2 Phase 4; Immunology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Diclofenac Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Bone Fracture; Osteoarthritis; Blood Gas Analysis; Elbow Pain | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06918340 | Diclofenac | Phase 4 | Blood Gas Analysis | Other | Dec 2024 |
| NCT05883241 | Diclofenac | Phase 1 | Bone Fracture | Other | Feb 2026 |
| NCT05254574 | Diclofenac | Phase 1 | Osteoarthritis | Immunology | May 2026 |
| NCT06373978 | Diclofenac | Phase 4 | Elbow Pain | Other | Jun 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.